Dabigatran Versus Conventional Treatment for Prevention of Silent Cerebral Infarct in Atrial Fibrillation Associated With Valvular Disease

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.

Also called NCT02982850

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 120 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02982850
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02982850. Randomized; no masking; primary purpose treatment. Start 2016-12 (registry gives no type); primary completion 2020-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Dabigatran Versus Conventional Treatment for Prevention of Silent Cerebral Infarct in Atrial Fibrillation Associated With Valvular Disease
Acronym
DECISIVE
Condition
Valve Heart Disease
Intervention (Drug)
Dabigatran
Intervention (Drug)
Acetylsalicylic acid
Intervention (Drug)
Warfarin
Lead sponsor
Asan Medical Center (class: other)
Collaborator
Boehringer Ingelheim (class: industry)

Record details

Record id
cardio:ct-nct02982850
Content hash
76c170d3906db206bf8f6171643bc800d6e394eda6afa29fd9afb74d88713aa9